North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane-Reference-Cited by-同舟云学术

North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane

Published:2012-12 Issue:6 Volume:12 Page:387-391
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Sideras Kostandinos,Dueck Amylou C.,Hobday Timothy J.,Rowland Kendrith M.,Allred Jacob B.,Northfelt Donald W.,Lingle Wilma L.,Behrens Robert J.,Fitch Tom R.,Nikcevich Daniel A.,Perez Edith A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies;Gennari;Cancer,2005

2. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review;Dawood;J Clin Oncol,2010

3. Breast cancer statistics, 2011;Desantis;CA Cancer J Clin,2011

4. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications;Ferrara;Semin Oncol,2002

5. The biology of VEGF and its receptors;Ferrara;Nat Med,2003

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC);Journal of Nanoparticle Research;2024-05

2. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2023-12-23

3. Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis;Medicine;2023-09-01

4. Angiogenesis Inhibition in Breast Cancer;Breast Disease;2019

5. Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer;Her2-Positive Breast Cancer;2019